PacBio: New Major Projects in DNA Sequencing Ignite Hope for a Turnaround

The stock of PacBio (Pacific Biosciences of California) lost nearly all of its value between July 2023 and May 2025. The 95% price drop was primarily due to a revenue decline of 23.2% in the fiscal year 2024, as well as the high losses incurred over the past three years. It is thus questionable whether the company can still achieve a successful turnaround or if the stock is lost. However, PacBio has not given up in any way. Since the end of May, the stock has risen by 80%. Over the past two days, further promising news followed, and from 2026 onward,...